450 related articles for article (PubMed ID: 16837130)
21. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
22. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
23. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
24. Cimetidine inhibits epidermal growth factor-induced cell signaling.
Fujikawa T; Shiraha H; Nakanishi Y; Takaoka N; Ueda N; Suzuki M; Shiratori Y
J Gastroenterol Hepatol; 2007 Mar; 22(3):436-43. PubMed ID: 17295779
[TBL] [Abstract][Full Text] [Related]
25. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
Zhou Y; Brattain MG
Cancer Res; 2005 Jul; 65(13):5848-56. PubMed ID: 15994962
[TBL] [Abstract][Full Text] [Related]
26. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
29. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Fuke H; Shiraki K; Sugimoto K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Masuya M; Takei Y
Biochem Biophys Res Commun; 2007 Nov; 363(3):738-44. PubMed ID: 17904524
[TBL] [Abstract][Full Text] [Related]
30. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
32. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.
Qiu L; Zhou C; Sun Y; Di W; Scheffler E; Healey S; Kouttab N; Chu W; Wan Y
Int J Oncol; 2006 Oct; 29(4):1003-11. PubMed ID: 16964397
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor in cultured human retinal pigment epithelial cells.
Yan F; Hui YN; Li YJ; Guo CM; Meng H
Ophthalmologica; 2007; 221(4):244-50. PubMed ID: 17579290
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
Zolfaghari A; Djakiew D
Prostate; 1996 Apr; 28(4):232-8. PubMed ID: 8602399
[TBL] [Abstract][Full Text] [Related]
36. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
[TBL] [Abstract][Full Text] [Related]
37. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.
Camaj P; Seeliger H; Ischenko I; Krebs S; Blum H; De Toni EN; Faktorova D; Jauch KW; Bruns CJ
Biol Chem; 2009 Dec; 390(12):1293-302. PubMed ID: 19804359
[TBL] [Abstract][Full Text] [Related]
38. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Ninomiya S; Shimizu M; Imai K; Takai K; Shiraki M; Hara T; Tsurumi H; Ishizaki S; Moriwaki H
Cancer Prev Res (Phila); 2011 Dec; 4(12):2092-100. PubMed ID: 21952585
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
40. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.
Castillo J; Erroba E; Perugorría MJ; Santamaría M; Lee DC; Prieto J; Avila MA; Berasain C
Cancer Res; 2006 Jun; 66(12):6129-38. PubMed ID: 16778186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]